Home | Contact | Incident Reporting | Sitemap | Santen Worldwide

Text Size

A
A
A

What's New

News Release

Apr 1, 2020 Santen Pharmaceutical measures to combat the disease caused by the novel coronavirus (COVID-19)
Mar 25, 2020 Intravitreal VEGF Inhibitor EYLEA approved as a Treatment of Neovascular Glaucoma (NVG), its fifth indication
Mar 24, 2020 Santen's Measures To Combat Novel Coronavirus (COVID-19) Infections
Mar 13, 2020 Notice of Corporate Officer Appointments
Mar 10, 2020 Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
Mar 5, 2020 Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020)
Feb 27, 2020 Beware of Suspicious E-mails and Messages on Social Media Claiming to be from Santen Pharmaceutical Co., Ltd.
Feb 18, 2020 Notice of personnel change
Feb 4, 2020 Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices
Feb 4, 2020 Santen Reports the 3rd Quarter Fiscal 2019 Consolidated Performance
Jan 23, 2020 Santen Pharmaceutical Selected as Title Sponsor of IBSA Blind Football World Grand Prix 2020!
Jan 10, 2020 Santen Pharmaceutical Signs Partnership Agreement with ITU Supporting ITU and WHO initiative 'Be He@lthy, Be Mobile' in Ophthalmology
Jan 6, 2020 Santen Announces the Construction of China Second Plant

Working at Advanced Vision Science

Working at Advanced Vision Science